Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial

Fig. 5

Swimming plot of survival. Each lane indicates one patient, ranked by the survival time. Corresponding sequence numbers of patients are labeled on the left. Characteristics of patients are shown on the top. No disease progression and death happened until writing. The median follow-up from the first day of treatment was 10.5 months, ranging from 6 to 18 months

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us